Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
18. Dezember 2023 07:00 ET
|
Achilles Therapeutics PLC
LONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
13. November 2023 16:30 ET
|
Achilles Therapeutics PLC
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1...
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
22. September 2023 16:30 ET
|
Achilles Therapeutics PLC
LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
04. August 2023 07:00 ET
|
Achilles Therapeutics PLC
- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - - neoRanker™ immunogenicity prediction module of PELEUS™...
Achilles Therapeutics to Present at Upcoming Conferences
12. Juni 2023 08:00 ET
|
Achilles Therapeutics PLC
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors,...
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
10. Mai 2023 07:15 ET
|
Achilles Therapeutics PLC
- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 - - Strong cash position of $158.5...
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
10. Mai 2023 07:00 ET
|
Achilles Therapeutics PLC
LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
25. April 2023 18:00 ET
|
Achilles Therapeutics PLC
LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
25. April 2023 07:00 ET
|
Achilles Therapeutics PLC
- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient’s tumor - - Patent applies to any modality, including vaccine and...
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
17. April 2023 08:00 ET
|
Achilles Therapeutics PLC
LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid...